Impact BioMedical Inc. develops and patents healthcare technologies for biopharmaceutical, consumer health and wellness applications. News about IBO centers on intellectual-property milestones, technology platforms such as 3F™, Linebacker™ and Equivir™, and partner-based paths for research, licensing, co-development and commercialization.
Company updates also cover portfolio activity in infectious-disease control, inflammatory disease, oncology evaluation and air purification technology, along with capital-structure actions, shareholder communications, market-action statements, governance matters and financial-reporting disclosures such as going-concern audit language.
DSS (DSS) and Impact Biomedical (IBO) report that Zoar Limited has filed a Registration Statement on Form F-4 with the SEC for the previously announced proposed business combination among Impact, Zoar and certain related parties.
DSS is a significant stockholder of Impact Biomedical and views the filing as an important milestone toward completing the transaction, which DSS’s CEO says could enhance Impact’s platform, growth opportunities and potential value for DSS shareholders. The Form F-4 includes a preliminary proxy statement of Impact and a prospectus of Zoar relating to the proposed transaction and remains subject to SEC review and effectiveness.
The business combination is still contingent on several conditions, including SEC declaration of effectiveness, approval by Impact stockholders, approval of the listing of Zoar ordinary shares on NYSE American, and satisfaction or waiver of other conditions in the merger and share exchange agreement.
Impact Biomedical (IBO) announced that Zoar Limited has filed a Form F-4 registration statement with the SEC on September 10, 2026, in connection with the previously disclosed business combination among Impact, Zoar Limited (PubCo) and Zoar Labs Limited. The filing includes Impact’s preliminary proxy statement and is available under “Zoar Limited” on the SEC’s website.
Impact’s management views the F-4 filing as a major milestone toward closing the merger. Completion of the business combination and listing of PubCo’s ordinary shares on NYSE American remain subject to the Form F-4 being declared effective by the SEC, approval by Impact stockholders, NYSE American listing approval, and other conditions in the merger and share exchange agreement. Upon approval and closing, the combined company is expected to focus on development and supply of active pharmaceutical ingredients and intermediates for specific therapeutic treatment areas.
Impact Biomedical (IBO) will implement a 1-for-12.62 reverse stock split of its common stock effective 12:01 a.m. Eastern Time on September 23, 2026, in connection with its proposed merger with Zoar Limited.
This corrected release clarifies that, upon completion of the merger, Impact stockholders are expected to receive one Zoar Limited share for every one Impact common share held immediately before the merger’s effective time, after the reverse split, rather than the previously stated 1-for-4 ratio. The split will reduce outstanding common shares from approximately 107,821,231 to about 8,543,679, subject to minor rounding. Every 12.62 existing shares will be combined into one new share, with fractional entitlements rounded up to a whole share. The split is intended to support the merger and NYSE American continued-listing objectives but does not assure listing compliance, listing application approval, or completion of the transaction.
Impact BioMedical (IBO)/b) will implement a 1‑for‑12.62 reverse stock split of its common stock effective 12:01 a.m. Eastern Time on September 23, 2026, as it pursues completion of a proposed merger with Zoar Ltd.After the split, IBO will continue trading on the NYSE American under ticker “IBO” with a new CUSIP. The split, approved by stockholders on December 30, 2025 within a 1‑for‑12.48 to 1‑for‑50 range, is intended to support a business‑combination transaction and NYSE American continued‑listing objectives, but does not assure listing compliance or deal completion. Every 12.62 shares of common stock will be combined into one share, reducing outstanding shares from approximately 107,821,231 to 8,543,679, subject to rounding. Fractional shares will be rounded up to the next whole share and percentage ownership will remain unchanged except for such rounding.
Impact BioMedical (NYSE American: IBO) disclosed that its Form 10-K for the year ended December 31, 2025, filed March 11, 2026, includes an audit opinion from Grassi & Co. with a going concern qualification. The company said this public notice complies with NYSE American Section 610(b) and does not amend its 2025 financial statements. Separately, Impact BioMedical continues strategic plans to merge with Dr. Ashley’s with a projected completion date of July 1, 2026.
Impact Biomedical (IBO) has secured U.S. patent No. 12,357,584 B2 for its 3F™ technology platform, focusing on controlling infectious diseases through plant-based functional fragrances. The patent, valid until December 2038, covers unique compositions with antimicrobial and antiviral properties effective against various pathogens including E. coli, MRSA, influenza, rhinovirus, and M. tuberculosis.
The technology addresses the growing infectious disease market, projected to expand from $21.7B in 2024 to $34B in 2023, with a CAGR of 5.77%. The company is actively pursuing partnerships to commercialize 3F™ technology in the US and globally.
Impact BioMedical (NYSE American: IBO) released a statement on March 21, 2025, addressing unusual market activity in its stock price. The company confirmed that there have been no material developments in its business operations beyond what has been previously disclosed to the public. The biotechnology company, which focuses on discovering, developing, and patenting innovative healthcare solutions, stated it is unaware of any other reasons that could explain the unusual trading activity in its shares.
Impact BioMedical Inc. (NYSE American: IBO) has announced the acquisition of Celios®, an air purification technology company, in an all-equity transaction valued at $1.15 million. The strategic acquisition expands IBO's portfolio with patented air purification technology that delivers virtually clean room air quality.
Celios® brings design, system, and method patents with exclusivity through 2043, featuring U.S. manufactured filter technology that is both highly effective and portable. The acquisition aligns with Impact BioMedical's roll-up strategy, aiming to generate immediate revenue while maintaining their current cash position.
Impact BioMedical Inc. (NYSE American: IBO) has announced its participation in The Microcap Conference 2025, scheduled for January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. CEO Frank D. Heuszel will deliver a corporate presentation on Wednesday, January 29, 2025, at 10:30 AM ET.
During the conference, Heuszel will conduct one-on-one meetings with investors to discuss the company's recent developments, growth strategy, and investment opportunities. Impact BioMedical, a biotechnology company, focuses on discovering, confirming, and patenting unique science and technologies for development into biopharmaceuticals and consumer healthcare solutions through various collaborative relationships including research, licensing, co-development, and joint ventures.